Technical Analysis for SMMT - Summit Therapeutics plc

Grade Last Price % Change Price Change
C 20.11 -2.71% -0.56
SMMT closed down 2.71 percent on Friday, February 7, 2025, on 63 percent of normal volume.
5 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Fell Below 20 DMA Bearish -2.71%
NR7 Range Contraction -2.71%
Inside Day Range Contraction -2.71%
Wide Bands Range Expansion -2.71%
20 DMA Support Bullish -3.22%
Wide Bands Range Expansion -3.22%
Crossed Above 20 DMA Bullish -2.47%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 17 hours ago
Down 3% about 17 hours ago
Down 2 % about 18 hours ago
Down 1% about 18 hours ago
20 DMA Resistance about 18 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Summit Therapeutics plc Description

Summit Corporation plc, a drug discovery and development company, engages in the discovery and development of novel drug candidates to treat areas of high unmet medical need. The company licenses its drug discovery platform, known as Seglin technology, for the identification of new drug leads and candidates with the potential to target a range of diseases. Its pipeline consists of clinical stage programmes targeting Duchenne Muscular Dystrophy (DMD) and Clostridium difficile infection (CDI). The company provides SMT C1100, a small molecule Utrophin modulator for DMD patients that has completed Phase I clinical trial; and SMT 19969, a Phase I clinical trial completed novel molecule antibiotic for the treatment for initial CDI and prevention of recurrent disease. It is also engaged in other programmes that include OGA inhibitor programme for the treatment of dementia. The company has a technology license agreement with Bristol-Myers Squibb to access the Seglin technology platform. It has operations primarily in the United Kingdom and the United States. The company was formerly known as VASTox plc and changed its name to Summit Corporation Plc in July 2007. Summit Corporation plc was founded in 2003 and is headquartered in Abingdon, the United Kingdom.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Disease Drug Discovery Antibiotics Dementia Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Summit Duchenne Cdi Clostridium Difficile Infection Clostridioides Difficile Clostridium Difficile

Is SMMT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Comments

Indicators

Indicator Value
52 Week High 33.89
52 Week Low 2.1
Average Volume 2,148,754
200-Day Moving Average 14.62
50-Day Moving Average 19.32
20-Day Moving Average 20.84
10-Day Moving Average 21.47
Average True Range 1.40
RSI (14) 48.19
ADX 16.72
+DI 21.63
-DI 23.22
Chandelier Exit (Long, 3 ATRs) 20.79
Chandelier Exit (Short, 3 ATRs) 20.67
Upper Bollinger Bands 25.35
Lower Bollinger Band 16.33
Percent B (%b) 0.42
BandWidth 43.28
MACD Line 0.46
MACD Signal Line 0.74
MACD Histogram -0.2812
Fundamentals Value
Market Cap 14.83 Billion
Num Shares 737 Million
EPS -0.24
Price-to-Earnings (P/E) Ratio -83.79
Price-to-Sales 753.90
Price-to-Book 32.05
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.76
Resistance 3 (R3) 21.86 21.40 21.49
Resistance 2 (R2) 21.40 20.98 21.36 21.39
Resistance 1 (R1) 20.76 20.72 20.53 20.66 21.30
Pivot Point 20.30 20.30 20.19 20.26 20.30
Support 1 (S1) 19.66 19.88 19.43 19.56 18.92
Support 2 (S2) 19.20 19.62 19.16 18.83
Support 3 (S3) 18.56 19.20 18.74
Support 4 (S4) 18.46